Headquartered in Missoula, Montana, Inimmune focuses on developing the next generation of vaccines and immunotherapeutics. In partnership with the University of Montana’s Center for Translational Medicine, Inimmune has received over $30 million in National Institutes of Health (NIH) contracts and grants. In September, the Center for Translational Medicine was awarded a five-year, $33.4 million NIH award, the largest in the University’s history, to develop and perform clinical trials of opioid vaccines in collaboration with Inimmune, where Inimmune will serve as the project’s corporate manufacturing partner. The most recent achievement for this Montana company: a $22 million round led by Two Bear Capital out of Whitefish, Montana in July 2020. This is the largest Series A investment in Montana history. 

Inimmune participated in the ASCEND Business Advising Cohort in 2020 and has been engaged throughout the program with attendance at the webinar series and the BIO International convention, tallying over 45 meetings at BIO Digital 2021. Partnership between the University of Montana, an academic co-lead for the ASCEND Hub, and Inimmune has fostered the growth of UM’s research enterprise and has put Montana on the map for biotechnology innovation. 

Please join us in congratulating Dr. Evans and the entire Inimmune team on their accomplishments! To learn more about Inimmune, please visit their website: https://inimmune.com/.